Technical Paper

Effects of Two Distinct Psychoactive Microbes,   
*Lacticaseibacillus rhamnosus* JB-1 and *Limosilactobacillus reuteri* 6475, on Circulating and Hippocampal mRNA in Male Mice

Sandor Haas-Neill 1, Eiko Iwashita 1, Anna Dvorkin-Gheva 2 and Paul Forsythe 3,4\*

|  |
| --- |
|  |

1 The Brain Body Institute, St. Joseph’s Hospital, McMaster University, Hamilton, ON L8N 4A6, Canada; haasneis@mcmaster.ca (S.H.-N.); iwashite@mcmaster.ca (E.I.)

2 McMaster Immunology Research Centre, Department of Medicine, McMaster University,   
Hamilton, ON L8N 3Z5, Canada; dvorkin@mcmaster.ca

3 Division of Pulmonary Medicine, Department of Medicine, University of Alberta, 569 Heritage Medical Research Center, Edmonton, AB Canada T6G 2S2

4 Alberta Respiratory Centre, University of Alberta, Edmonton, AB, Canada

**\*** Correspondence: pforsyt1@ualberta.ca

**Abstract:** Discovery of the microbiota-gut–brain axis has led to proposed microbe-based therapeutic strategies in mental health, including the use of mood-altering bacterial species, termed psychobiotics. However, we still have limited understanding of the key signaling pathways engaged by specific organisms in modulating brain function, and evidence suggests that bacteria with broadly similar neuroactive and immunomodulatory actions can drive different behavioral outcomes. We sought to identify pathways distinguishing two psychoactive bacterial strains that seemingly engage similar gut–brain signaling pathways but have distinct effects on behaviour. We used RNAseq to identify mRNAs differentially expressed in the blood and hippocampus of mice following *Lacticaseibacillus rhamnosus* JB-1, and *Limosilactobacillus reuteri* 6475 treatment and performed Gene Set Enrichment Analysis (GSEA) to identify enrichment in pathway activity. *L. rhamnosus,* but not *L. reuteri* treatment altered several pathways in the blood and hippocampus, and the *rhamnosus* could be clearly distinguished based on mRNA profile. In particular, *L. rhamnosus* treatment modulated the activity of interferon signaling, JAK/STAT, and TNF-alpha via NF-KB pathways. Our results highlight that psychobiotics can induce complex changes in host gene expression, and in understanding these changes, we may help fine-tune selection of psychobiotics for treating mood disorders.

**Keywords:** depression; stress; gut–brain-axis; JB-1; psychobiotics; miRNA; mRNA; hippocampus; blood; microbiota

1. Introduction

Anxiety and depression are two of the most common mood disorders in the western world becoming increasingly prevalent in millennials and adolescents [1,2]. The COVID-19 pandemic only exacerbated the problem. Among adults in the UK the reported rate of depression symptoms nearly doubled from pre-to-post pandemic (10% to 19%), and in the US it nearly quadrupled (11% to 42%) [3]. Much attention has been given to the gut–brain-axis in recent years as it is beginning to revolutionize our understanding and treatment of mental health disorders [4].

Numerous direct and indirect interactions between bacteria endemic to the gut, and the central nervous system characterize what is known as the microbiota-gut–brain axis [5]. The introduction of certain bacteria to the gut that modulate brain function, termed psychoactive-probiotics or psychobiotics, have been demonstrated to influence behaviour in animal models and mood/anxiety in humans [6,7]. One such potential psychobiotic is *Lacticaseibacillus rhamnosus* JB-1, which has previously been shown to reduce anxiety and depression-like behaviours in mice [8–10].

It is incompletely understood how JB-1 facilitates these cognitive and behavioural changes, although both the peripheral nervous system and the immune system are critical mediators [8,9,11]. Specifically, feeding of JB-1 was only able to alleviate the depression and anxiety-like behaviours of mice when the vagus nerve was intact [9]. Feeding of JB-1 also results in modulation of the immune system and induces regulatory T cells, which have been demonstrated to be both necessary and sufficient to mediate the behavioral effects of the bacteria [8,11]. Other psychobiotics have been suggested to modulate behaviour and cognition via the endocrine system, the release of soluble metabolites including neurotransmitters into circulation, and the release of bacterial membrane vesicles (MV) carrying similar metabolites and RNAs into circulation [12–15]. Up to this point however these mechanisms have not been demonstrated to be involved in the behavioural changes induced by *L. rhamnosus* JB-1.

*Limosilactobacillus reuteri* 6475 (LR6475) is a probiotic bacteria that has previously been shown to modulate social behaviours; rescuing autism-spectrum-disorder-like social deficits induced by a maternal high-fat diet in mice [16]. Mechanistically, LR6475 achieves this in a vagus-dependant manner and by boosting oxytocin levels [17,18]. LR6475 has also been shown to have efficacy in treating irritable bowel syndrome and increase bone density via T-lymphocyte regulation [19,20]. However, despite both JB-1 and LR6475 engaging the vagus nerve and regulatory immune responses the bacteria have some distinct actions on behaviour with JB-1, but not LR6475, having antidepressant-like effects in mice [21]. The reasons for the distinct behavioral effects of the bacteria is unclear.

Here, in an attempt to identify potential pathways distinguishing two psychoactive bacterial strains that seemingly engage similar gut–brain signaling pathways but have distinct effects on behaviour, we compare transcriptomic changes in blood and hippocampus, a region of the brain responsible for memory and emotion and closely linked with depression [22–24], following feeding with JB-1 and LR6475.

2. Results

2.1. Many mRNAs and Gene Sets Are Altered in the Blood of JB-1-Fed Mice, but Not LR6475-Fed

Principal component analysis (PCA) of normalized, filtered mRNA in the blood of mice shows no distinct groups between PBS and LR6475 fed mice; however, JB-1 fed mice differ greatly from the cluster PBS and LR6475-fed mice form along both PC 1 and 2 (adonis *p*-value = 0.049) (Figure 1A). As the PCA indicates, many genes were found to be differentially expressed when comparing JB-1 to PBS-fed mice (Figure 1B) and a few-when comparing JB-1 to LR6475 (Figure 1D); however, no genes were significantly differentially expressed between LR6475 and PBS-fed mice. FKBP1A was among the genes upregulated in the blood of JB-1-fed mice in both comparisons.

**Diagram

Description automatically generated**

**Figure 1.** Differential expression analysis of mRNA measured by RNAseq in the blood of mice fed either *Lacticaseibacillus rhamnosus* JB-1, *Limosilactobacillus reuteri* 6475, or PBS. (**A**) Principal component analysis of all three treatment groups. (**B**) Volcano plot showing individual differentially expressed genes in a comparison of JB-1 vs. PBS-fed mice. (**C**) Volcano plot showing individual differentially expressed genes in a comparison of LR6475 vs. PBS-fed mice. (**D**) Volcano plot showing individual differentially expressed genes in a comparison of JB-1 vs. LR6475-fed mice. Genes with a positive log fold change are more highly expressed.

To elucidate additional sources of grouping along PC1 and 2 in the blood, Gene Set Enrichment Analysis was performed, comparing KEGG and Hallmark gene set expression in JB-1-fed mice to LR6475 and to PBS-fed independently. LR6475 and PBS-fed mice were not compared as their groups were not distinct in PCA. Many pathways from both KEGG and Hallmark were found differentially expressed in both directions, in both JB-1 comparisons, and are summarized in (Table 1). All of the pathways enriched in JB-1 vs. PBS were common to the JB-1 vs. LR6475 comparison, with the exception of KEGG\_LEUKOCYTE\_TRANSENDOTHELIAL\_MIGRATION, and KEGG\_NATURAL\_KILLER\_CELL\_MEDIATED\_CYTOTOXICITY which were enriched in PBS compared to JB-1 but did not appear significant in the JB-1 vs. LR6475 comparison. 1 Hallmark pathway and 4 KEGG pathways were commonly enriched in JB-1 for both comparisons, and 6 Hallmark and 8 KEGG pathways were commonly enriched in LR6475, and PBS compared to JB-1. Mouse gene names converted to human orthologs were used to visualize KEGG pathways in pathview-these figures were created for the blood mRNA JB-1 vs. PBS comparison and can be found in the supplementary figures (Supplementary Figure S1–S18).

**Table 1.** Enriched pathways in JB-1 compared with PBS and compared with LR6475. The left column shows the relative direction of expression in JB-1 for each gene set and the right column shows the adjusted *p*-Value for each. Both JB-1 comparisons had nearly identical pathways and corresponding directions of expression, except for the last two entries on the table, which were significant only in the JB-1 vs. PBS comparison.

|  |  |  |
| --- | --- | --- |
| Enriched In | Pathway Name | Adj.*p*-Val (JvC, JvR) |
| JB-1 | HALLMARK\_OXIDATIVE\_PHOSPHORYLATION | 3.4 x 10-4, 3.4 x 10-4 |
| JB-1 | KEGG\_OXIDATIVE\_PHOSPHORYLATION | 3.7 x 10-3, 9.9 x 10-3 |
| JB-1 | KEGG\_PARKINSONS\_DISEASE | 1.3 x 10-2, 2.3 x 10-2 |
| JB-1 | KEGG\_HUNTINGTONS\_DISEASE | 1.3 x 10-2, 2.3 x 10-2 |
| JB-1 | KEGG\_ALZHEIMERS\_DISEASE | 2.1 x 10-2, 3.7 x 10-2 |
| PBS | HALLMARK\_ALLOGRAFT\_REJECTION | 1.5 x 10-6, 2.7 x 10-6 |
| PBS | HALLMARK\_INTERFERON\_GAMMA\_RESPONSE | 5.4 x 10-6, 8.9 x 10-6 |
| PBS | HALLMARK\_INFLAMMATORY\_RESPONSE | 4.6 x 10-3, 9.4 x 10-3 |
| PBS | HALLMARK\_INTERFERON\_ALPHA\_RESPONSE | 7.7 x 10-3, 8.3 x 10-3 |
| PBS | HALLMARK\_TNFA\_SIGNALLING\_VIA\_NFKB | 3.2 x 10-2, 3.1 x 10-2 |
| PBS | HALLMARK\_IL6\_JAK\_STAT3\_SIGNALLING | 3.2 x 10-2, 2.5 x 10-2 |
| PBS | KEGG\_PRIMARY\_IMMUNODEFICIENCY | 1.5 x 10-3, 3.6 x 10-3 |
| PBS | KEGG\_CYTOKINE\_CYTOKINE\_RECEPTOR\_INTERACTION | 4.9 x 10-3, 9.2 x 10-3 |
| PBS | KEGG\_JAK\_STAT\_SIGNALLING\_PATHWAY | 4.9 x 10-3, 8.0 x 10-3 |
| PBS | KEGG\_CHEMOKINE\_SIGNALLING\_PATHWAY | 1.8 x 10-2, 1.0 x 10-2 |
| PBS | KEGG\_HEMATOPOIETIC\_CELL\_LINEAGE | 1.9 x 10-2, 1.0 x 10-2 |
| PBS | KEGG\_B\_CELL\_RECEPTOR\_SIGNALLING\_PATHWAY | 1.9 x 10-2, 2.8 x 10-2 |
| PBS | KEGG\_RIBOSOME | 2.1 x 10-2, 6.7 x 10-3 |
| PBS | KEGG\_T\_CELL\_RECEPTOR\_SIGNALLING\_PATHWAY | 2.2 x 10-2, 2.8 x 10-2 |
| PBS | KEGG\_LEUKOCYTE\_TRANSENDOTHELIAL\_MIGRATION | 3.8 x 10-2, N/S |
| PBS | KEGG\_NATURAL\_KILLER\_CELL\_MEDIATED\_CYTOTOXICITY | 4.5 x 10-2, N/S |

2.2. Few mRNAs and Gene Sets Are Altered in the Hippocampus of Psychobiotic-Fed Mice

In the principal component analysis of normalized, filtered mRNA in the hippocampus of mice, JB-1 and LR6475-fed do not form distinct clusters from one another; however, both JB-1 and LR6475-fed mice differ from the PBS cluster formed along both PC1 and 2 (adonis *p*-value = 0.17) (Figure 2A). Only 2 genes, TPPP3 and SGK1 were found to be differentially expressed when comparing JB-1 to PBS-fed mice (Figure 2B). When comparing JB-1 to LR6475, and LR6475 to PBS-fed mice (Figure 2C,D); however, no genes were found to be significantly differentially expressed. In order to identify sources of the group distinction for both PBS comparisons, Gene Set Enrichment Analysis was performed.

**Diagram

Description automatically generated**

**Figure 2.** Differential expression analysis of mRNA measured by RNAseq in the hippocampus of mice fed either *Lacticaseibacillus rhamnosus* JB-1, *Limosilactobacillus reuteri* 6475, or PBS. (**A**) Principal component analysis of all three treatment groups. (**B**) Volcano plot showing individual differentially expressed genes in a comparison of JB-1 vs. PBS-fed mice. (**C**) Volcano plot showing individual differentially expressed genes in a comparison of LR6475 vs. PBS-fed mice. (**D**) Volcano plot showing individual differentially expressed genes in a comparison of JB-1 vs. LR6475-fed mice. Genes with a positive log fold change are more highly expressed.

Enrichment analysis of hippocampal mRNA following treatment was also poorly able to identify the source of PCA group distinction. No Hallmark pathways were found differentially expressed in any of the three comparisons. KEGG\_RIBOSOME was enriched in the hippocampi of both JB-1 (adj.*p*-value = 1.3 x 10-4) and LR6475-fed mice (adj.*p*-value = 2.4 x 10-7) compared to PBS-fed mice, and KEGG\_VIBRO\_CHOLERAE\_INFECTION was enriched in PBS compared to LR6475 (adj.*p*-value = 1.6 x 10-2). With so few discerning features between individual gene expression and enrichment analysis, it remains unclear what is driving the distinction seen between PBS and the other treatment groups in the PCA. Additional PCs were checked (up to PC12) but none alone explain the distinction.

3. Discussion

Here, we examined blood and hippocampal transcriptional changes induced by two lactobacillus species that have previously been demonstrated to have distinct effects on behaviour in mice [8–10,16,21]. This study identified clear transcriptomic changes in the blood, and to a lesser extent, the hippocampus following feeding with JB-1, but not LR6475.

3.1. Inflammatory Response

Immunomodulatory actions have been described for both JB-1 and LR6475 and in the case of JB-1 these have been demonstrated to mediate effects on behaviour [8–10,16]. The current study identified transcriptomic changes reflective of immunomodulation. In particular, several genes involved in antigen presentation were enriched in the PBS and LR6475 vs. JB-1 (Figure 1B,D). Histocompatibility 2, class II antigen A, alpha (H2-Aa), a subunit of the major histocompatibility complex II (MHCII) enables peptide antigen binding activity, and it participates in the interferon-𝛾 response [25]. Additionally, enriched in the blood of PBS and LR6475 vs. JB-1 was gamma-interferon-inducible lysosomal thiol reductase (IFI30) an enzyme that reduces endocytic disulphide bonds to bring about production of MHC class II-restricted epitopes [26,27]. B-cell antigen receptor complex-associated protein alpha chain and beta chain (CD79a and CD79b) were both enriched in the blood of PBS and LR6475 compared to JB-1-fed mice. These proteins cooperate, and are required for antigen presentation on B cells, as they facilitate the signal transduction cascade activated by an antigen binding to the B cell antigen receptor complex [28,29]. There are several lines of evidence suggesting JB-1 has physiological effects similar to selective serotonin reuptake inhibitors (SSRIs) [10,21,30]. It is therefore interesting to note that SSRIs such as fluoxetine have also been shown to modulate antigen presentation, reducing co-stimulatory marker expression on dendritic cells and subsequent antigen induced T cell response [31].

We also observed marked changes in mRNA related interferon signaling with significant diminution of HALLMARK\_INTERFERON\_ALPHA\_RESPONSE, HALLMARK\_INTERFERON\_GAMMA\_RESPONSE, and HALLMARK\_INFLAMMATORY\_RESPONSE in the blood of mice treated with JB-1 in comparison to both PBS and reuteri 6475. The Interferons are known to play a role in the link between the immune system and mood disorders. INF-ɑ is used to treat hepatitis C and is associated with a 30–70% increased risk of emergent depression [32]. Interferon gamma (INF-γ) is also indicated to play a role in depression [33]. Patients with MDD demonstrate higher levels of INF-γ production by peripheral blood mononuclear cells [34] and successful antidepressant treatment decreases levels of this inflammatory cytokine while increasing regulatory IL-10 [35]. Furthermore INF-γ −/− mice demonstrate decreased anxiety- and depressive-like behaviors. More broadly, inflammatory cytokines including INF-γ are upregulated as part of the stress response, which in turn leads to activation of the microglia, hypothalamic-pituitary-adrenal (HPA) axis, and the sympathetic nervous system (SNS) [33]. Our observation of decreased INF-ɑ, INF-γ, and inflammatory pathway activity in the blood, indicates a broad anti-inflammatory effect of JB-1 and is consistent with our previous findings of increased regulatory T cells and inhibition of mast cell degranulation [8,36,37]. Additional evidence for a general anti-inflammatory response to JB-1 is indicated by the decreased expression of the KEGG\_T\_CELL\_RECEPTOR\_SIGNALLING\_PATHWAY in the blood of JB-1 treated mice compared to both LR6475 treated and control animals. The T cell receptor signaling pathway is critical for the activation of T lymphocytes (CD25+) which have previously been found elevated in the blood of depressed individuals [38]. The JB-1 associated differences in circulating gene expression of interferon signaling pathways was not observed in the hippocampus.

HALLMARK\_TNFA\_SIGNALLING\_VIA\_NFKB was underexpressed in both JB1 blood comparisons. These are genes that are regulated by NF-KB in response to TNF-𝞪. TNF-𝞪 signaling through NF-KB has previously been shown to activate microglia and increase neuroinflammation in mice showing depression-like behaviour [39]. Mice instilled with depressive-like behaviour via chronic unpredictable mild stress also showed heightened levels of inflammatory cytokines, and NF-KB in the prefrontal cortex and hippocampus, the signaling of which was associated with greater risk of depressive symptoms [40].

Finally, FKBP12, one of the genes increased in expression in the blood of JB-1-fed animals compared to the other treatment groups, is a known inhibitor of mTOR signaling [41]. This may be part of the anti-inflammatory response to JB-1, as mTOR controls immune cell activity as well through assisting the differentiation of T cells, and by regulating translation, modulating cytokine responses, macrophage migration and polarization, and antigen presentation [41–44].

3.2. Cerebral Cortical Signaling

The Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway controls several processes in the cerebral cortex and hippocampus, including microglial activation, synaptic plasticity, gliogenesis, and neurogenesis [45–47]. Here, we found it downregulated in the blood mRNA for both the Hallmark and KEGG gene sets (HALLMARK\_IL6\_JAK\_STAT3\_SIGNALING, KEGG\_JAK\_STAT\_SIGNALING\_PATHWAY). Al-Samhari et al. (2016) [48] found that treating rats with antioxidant precursor, N-acetylcysteine, inhibited STAT3 protein activation led to reduced depression-like symptoms in rats (increased locomotor activity). This is one example of why it has been proposed that JAK/STAT pathway inhibitors could serve as good candidates for antidepressants [48,47]. The reduced expression of the JAK/STAT pathway in the blood of mice after JB1 feeding suggests this may be a previously unrecognized mechanism contributing to the antidepressant-like effects of the bacteria.

Within all comparisons made, only two genes were significantly overexpressed in the hippocampus-TPPP3 and SGK1 which were alteredin the JB-1 vs. PBS-fed comparison. Tubulin polymerization-promoting protein family member 3 (TPPP3) is a protein that regulates microtubule dynamics [49], and Serine/threonine-protein kinase Sg1k (SGK1) is a kinase that regulates a variety of ion channels, transcription factors, cellular enzymes, cell growth, membrane transporters, and is known to play a significant role in the stress response [50–53]. SGK1, is a negative regulator of VEGF and BDNF, has been shown to interact with NF-KB, RAN, mTOR, FOXO3A, and is increased in a human hippocampal progenitor cell line during MDD, and decreased in the prefrontal cortex of PTSD patients [54–56]. Licznerski et al. (2015) [56] also found that in the hippocampus of foot-shock stressed rats, SGK1 mRNA was underexpressed, but the amount of hippocampal protein remained unchanged. Zhang et al. (2016) [57] found that in a chronic corticosterone (CORT) mouse model for anxiety and depression, glucocorticoid receptor levels were diminished, leading to an insufficient hippocampal neurogenesis. By treating mice with baicalin, they were able to restore hippocampal neurogenesis and reverse depression-like behaviours [57]. In their model, baicalin is thought to be undoing phosphorylation of SGK1, allowing it to phosphorylate the glucocorticoid receptor, encouraging translation to the nucleus, where it may promote neurogenesis.

3.3. JB-1-Modulated Genes in the Blood

Several mRNAs were upregulated in the blood of JB1-fed mice compared to both LR6475 and PBS-fed mice. They were: FKBP1A, SNRPN, CELF4, GPM6B, APBB1, NCDN, RUNDC3A, CPE, and CLSTN1.

Neuronal membrane glycoprotein gene (GPM6B) codes for a protein involved in bone formation and osteoblast function, as well as being a binding partner of the serotonin transporter (SERT) [58,59]. It has been suggested that GPM6B could play a role in regulating SERT cellular trafficking and activity, which could potentially have a broad impact on mood disorders [59,60]. It has also been found that GPM6B expression is severely reduced in the hippocampus of depressed suicides, and mechanistically, it has been proposed that this lack of GPM6B in the hippocamus alters oligodendrocyte function to contribute to MDD [61,62].

Carboxypeptidase E (CPE) codes for an exopeptidase that removes C-terminal lysine or arginine acids from peptides [63]. Rodriguiz et al. (2013) [63] found that a point mutation to the CPE gene induced anxiety-like behaviours in older mice, and depression-like behaviours in mice of all ages. Anxiety-like behaviours were reversed following acute treatment with fluoxetine or diazapam, while depression-like behaviours were reversed with acute reboxetine administration, or prolonged treatment with bupropion or fluoxetine [63]. A similar mutation was discovered in an Alzheimer’s patient by Cheng et al. (2016) [64] and replicating the mutation in mice led to decreased neurogenesis in the hippocampus, decreased dendrites, impaired memory, and depression-like behaviour.

Calsyntenin-1 (CLSTN1) codes for a protein that encourages vesicle association with KLC1 in axonal anterograde transport [65]. CLSTN1 has previously been found to be differentially hypermethylated in the blood of MDD patients (*n* = 118) compared to healthy subjects (*n* = 236) [66]. The mechanism by which CLSTN1 affects depression has yet to be elucidated, however Li et al. (2021) [67] confirmed that overexpression of CLSTN1 in the hippocampus of mice and rats increased anxiety and depression-like phenotypes. We did not find that JB1 altered hippocampal expression of CLSTN1, and it is interesting that we see it increased in the blood. As the differentially methylated DNA samples in Davies et al. (2014) [66] were collected from the blood, this suggests that a dearth of CLSTN1 expression in the body is implicated in depression.

4. Materials and Methods

4.1. Laboratory Methods

4.1.1. Feeding and Tissue Collection

7–9-week-old male balb/c mice from Charles River Laboratories were orally gavaged with 200 µL of either *Lacticaseibacillus rhamnosus JB*-1 (2 × 10⁹), *Limosilactobacillus reuteri* 6475 (2 × 10⁹), or PBS (*n* = 5, 5, 5). Mice were gavaged once per day for 2 weeks and sacrificed 3 h after the last gavage. Trunk blood was collected and whole brains were flash frozen and stored. Later, hippocampi of alternating side half brains were isolated and stored for RNA isolation.

4.1.2. RNA Isolation and Analysis

Total RNA was isolated from fresh whole blood using a PureLink RNA mini kit for total RNA isolation and using the manufacturer-recommended protocol for whole blood extraction.

Total RNA from hippocampi was isolated first by homogenizing the tissue with mortar and pestle in lysis buffer, followed by up-down pipetting through a 27-gauge syringe. After the tissue was completely homogenized, the same PureLink RNA mini kit was used to extract total RNA using the manufacturer-recommended protocol for tissue extraction.

Four samples from each gavage group, totaling at 12 samples for blood and hippocampus, underwentpaired-end RNAseq (P3, 2 × 50 bp) on an illumina NextSeq for mRNA discovery and analysis.

4.2. Bioinformatic and Statistical Analysis

4.2.1. Data Preprocessing and Differential Expression

Raw RNAseq data were adaptor trimmed and aligned using the ‘RNA-Seq Alignment’ app in Illumina BaseSpace which uses the Spliced Transcripts Alignment to a Reference (STAR) alignment method with the USCS mm10 refseq gene annotation file [68]. Next transcript expression of the annotation data was quantified by Salmon to produce count data [69] within the ‘RNA-Seq Alignment’ app, variant calling was performed by Strelka Variant caller [70], quality control metrics were performed by picard. Raw count data were downloaded, and differential expression was performed by using ‘DESeq2′ package in R [71], which automatically filters low expressed genes and normalizes the data by the geometric mean. Individual mRNAs were considered to be differentially expressed when they exhibited adjusted *p*-value < 0.05, and an |FC| > 1.5. *p*-values were adjusted using Benjamini–Hochberg method [72].

4.2.2. PCA

Percent variables and principal components were calculated using DESeq2′s plotPCA function on the list of internally normalized and filtered genes, and then graphed using ggplot2 [73].

4.2.3. Enrichment Analysis

Fold change and adjusted *p*-values values generated by DESeq2′s ‘results’ function were used by the generally applicable *gage* (gene-set enrichment for pathway analysis) package in R to generate enrichment results to the KEGG and Hallmark pathway gene sets [74]. KEGG pathway visualization was performed using the ‘pathview’ R package [75] and shows relative expression of each gene in each differentially expressed pathway (determined by gage). Enrichment of a certain pathway was considered significant at Benjamini–Hochberg adjusted *p*-value < 0.05.

5. Conclusions

Here, we identified several pathways and genes that may be associated with JB-1, treatment that may plausibly be related to the effects of these organisms on behavior, summarized in (Tables 2 and 3). Some are likely related to the previously described immunomodulatory effects of these organisms. In particular, the role interferon signaling pathways in mediating gut–brain signaling warrants further exploration. The lack of any significant modified pathways or genes following LR6475 is surprising. However, this study examined the direct effect of JB-1 and LR6475 on normal BALB/c mice, while this mouse strain has high trait anxiety it may be that the effects of LR6475 would only be observable following a stress challenge or in a pathological mood disorder model.

**Table 2.** Differential expression of pathways relevant to depression, in depression, after established antidepressant treatment, and following JB-1 treatment in mice. The up and down arrows represent the direction of change in pathway expression in our findings and in literature.

|  |  |  |  |
| --- | --- | --- | --- |
| Pathway | INF-𝞬/INF-𝞪 | JAK/STAT | TNF-𝞪 Via NF-KB |
| Change in Depression | ↑ generally increased, but suboptimal expression has also been associated with depression [33,76,77] | ↑ activation in stress and depression in mice [78] | ↑ in prefrontal cortex and hippocampus of mice [40] |
| Change in MDD Treatment | ↓ after treatment with either sertraline, clomipramine, or trazodone in human blood [35] | ↓ phosphorylation (activation) of Jak-3 returned to normal in mice following Amitriptyline treatment [78] | ↓ SSRIs such as imipramine reduce TNF-𝞪 levels in rats [79] |
| Blood Change Following JB-1 | ↓ mRNA (INF-𝞬 adj.p-val = 5.4 x 10-6)(INF-𝞪 adj.p-val = 7.7 x 10-3) | ↓ mRNA (adj.p-val = 4.9 x 10-3) | ↓ mRNA (adj.p-val = 3.2 x 10-2) |

**Table 3.** Differential expression of genes relevant to depression, in depression, after established antidepressant treatment, and following JB-1 treatment in mice. The up and down arrows represent the direction of change in pathway expression in our findings and in literature.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Gene | SGK1 | GPM6B | NCDN | CLSTN1 |
| Change in Depression | ↓ in hippocampus of rats [56] | ↓ in the hippocampus of humans [60] | ↓ in CNS of mice [80] | ↓ in blood of humans [66], ↑ in hippocampus of rats and mice [67] |
| Change in Depression Treatment | ↑ mRNA in hippocampus and prefrontal cortex of rats following icariin or baicalin treatment [81,82] | N/A | ↓ in hippocampus after ketamine treatment in rats [83] | N/A |
| Change Following JB-1 | ↑ mRNA in hippocampus of mice (adj.p-val = 4.5 x 10-2) | ↑ mRNA in blood of mice (adj.p-val = 7.6 x 10-4) | ↑ mRNA in blood of mice (adj.p-val = 8.5 x 10-3) | ↑ mRNA in blood of mice (adj.p-val = 1.6 x 10-2) |

There are certain limitations to the current study. The brains used in the study were not perfused following collection, and therefore could contain a small amount of blood from within capillaries in the hippocampus. Furthermore, only male mice were used, there is evidence that the outcome of gut–brain signaling can be sex dependent and thus sex comparisons would be worthy of examination in the future. This is particularly pertinent as in humans mental health disorders disproportionately affect women.

Overall, our results highlight that microbes labeled as psychobiotics, or potential psychobiotics, induce complex changes in systemic gene expression which are far from uniform between organisms. A better understanding of the many pathways impacted by individual organisms may help develop more tailored microbe-based approaches to specific mental health issues.

**Supplementary Materials:** The following supporting information can be downloaded at: www.mdpi.com/xxx/s1.

**Author Contributions:** Conceptualization, S.H.-N. and P.F.; methodology, S.H.-N. and A.D.-G.; formal analysis, S.H.-N.; investigation, S.H.-N. and E.I.; data curation, S.H.-N.; writing—original draft preparation, S.H.-N. and P.F.; writing—review and editing, P.F., A.D.-G. and S.H-N.; visualization, S.H.-N.; supervision, P.F. and A.D.-G. All authors have read and agreed to the published version of the manuscript.

**Funding:** PF is the AstraZeneca (Canada) Inc., Chair in Asthma and Obstructive Lung Disease.

**Institutional Review Board Statement:** The animal study was approved by the McMaster University’s Animal Research Ethics Board (18-05-23).

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

References

1. Wittchen, H.U.; Jacobi, F.; Rehm, J.; Gustavsson, A.; Svensson, M.; Jönsson, B.; Olesen, J.; Allgulander, C.; Alonso, J.; Faravelli, C.; et al. The Size and Burden of Mental Disorders and Other Disorders of the Brain in Europe 2010. *Eur. Neuropsychopharmacol.* **2011**, *21*, 655–679. https://doi.org/10.1016/j.euroneuro.2011.07.018.
2. Patalay, P.; Gage, S.H. Changes in Millennial Adolescent Mental Health and Health-Related Behaviours over 10 Years: A Population Cohort Comparison Study. *Int. J. Epidemiol.* **2019**, *48*, 1650–1664. https://doi.org/10.1093/ije/dyz006.
3. Abbott, A. COVID’s Mental-Health Toll: How Scientists Are Tracking a Surge in Depression. *Nature* **2021**, *590*, 194–195. https://doi.org/10.1038/d41586-021-00175-z.
4. Long-Smith, C.; O’Riordan, K.J.; Clarke, G.; Stanton, C.; Dinan, T.G.; Cryan, J.F. Microbiota-Gut-Brain Axis: New Therapeutic Opportunities. *Annu. Rev. Pharmacol. Toxicol.* **2020**, *60*, 477–502. https://doi.org/10.1146/annurev-pharmtox-010919-023628.
5. Carabotti, M.; Scirocco, A.; Maselli, M.A.; Severi, C. The Gut-Brain Axis: Interactions between Enteric Microbiota, Central and Enteric Nervous Systems. *Ann. Gastroenterol.* **2015**, *28*, 203–209.
6. Sarkar, A.; Lehto, S.M.; Harty, S.; Dinan, T.G.; Cryan, J.F.; Burnet, P.W.J. Psychobiotics and the Manipulation of Bacteria–Gut–Brain Signals. *Trends Neurosci.* **2016**, *39*, 763–781. https://doi.org/10.1016/j.tins.2016.09.002.
7. Wallace, C.J.K.; Milev, R. The Effects of Probiotics on Depressive Symptoms in Humans: A Systematic Review. *Ann. Gen. Psychiatry* **2017**, *16*, 14. https://doi.org/10.1186/s12991-017-0138-2.
8. Bharwani, A.; Mian, M.F.; Surette, M.G.; Bienenstock, J.; Forsythe, P. Oral Treatment with Lactobacillus Rhamnosus Attenuates Behavioural Deficits and Immune Changes in Chronic Social Stress. *BMC Med.* **2017**, *15*, 7. https://doi.org/10.1186/s12916-016-0771-7.
9. Bravo, J.A.; Forsythe, P.; Chew, M.V.; Escaravage, E.; Savignac, H.M.; Dinan, T.G.; Bienenstock, J.; Cryan, J.F. Ingestion of Lactobacillus Strain Regulates Emotional Behavior and Central GABA Receptor Expression in a Mouse via the Vagus Nerve. *Proc. Natl. Acad. Sci.* *USA* **2011**, *108*, 16050–16055. https://doi.org/10.1073/pnas.1102999108.
10. McVey Neufeld, K.-A.; Kay, S.; Bienenstock, J. Mouse Strain Affects Behavioral and Neuroendocrine Stress Responses Following Administration of Probiotic Lactobacillus Rhamnosus JB-1 or Traditional Antidepressant Fluoxetine. *Front. Neurosci.* **2018**, *12*, 294. https://doi.org/10.3389/fnins.2018.00294.
11. Liu, Y.; Mian, M.F.; McVey Neufeld, K.-A.; Forsythe, P. CD4+CD25+ T Cells Are Essential for Behavioral Effects of Lactobacillus Rhamnosus JB-1 in Male BALB/c Mice. *Brain. Behav. Immun.* **2020**, *88*, 451–460. https://doi.org/10.1016/j.bbi.2020.04.014.
12. Martin, A.M.; Sun, E.W.; Rogers, G.B.; Keating, D.J. The Influence of the Gut Microbiome on Host Metabolism Through the Regulation of Gut Hormone Release. *Front. Physiol.* **2019**, *10*, 428. https://doi.org/10.3389/fphys.2019.00428.
13. Dinan, T.G.; Stanton, C.; Cryan, J.F. Psychobiotics: A Novel Class of Psychotropic. *Biol. Psychiatry* **2013**, *74*, 720–726. https://doi.org/10.1016/j.biopsych.2013.05.001.
14. Choi, J.; Kim, Y.-K.; Han, P.-L. Extracellular Vesicles Derived from Lactobacillus Plantarum Increase BDNF Expression in Cultured Hippocampal Neurons and Produce Antidepressant-like Effects in Mice. *Exp. Neurobiol.* **2019**, *28*, 158–171. https://doi.org/10.5607/en.2019.28.2.158.
15. Haas-Neill, S.; Forsythe, P. A Budding Relationship: Bacterial Extracellular Vesicles in the Microbiota-Gut-Brain Axis. *Int. J. Mol. Sci.* **2020**, *21*, 8899. https://doi.org/10.3390/ijms21238899.
16. Sgritta, M.; Dooling, S.W.; Buffington, S.A.; Momin, E.N.; Francis, M.B.; Britton, R.A.; Costa-Mattioli, M. Mechanisms Underlying Microbial-Mediated Changes in Social Behavior in Mouse Models of Autism Spectrum Disorder. *Neuron* **2019**, *101*, 246–259.e6. https://doi.org/10.1016/j.neuron.2018.11.018.
17. Buffington, S.A.; Di Prisco, G.V.; Auchtung, T.A.; Ajami, N.J.; Petrosino, J.F.; Costa-Mattioli, M. Microbial Reconstitution Reverses Maternal Diet-Induced Social and Synaptic Deficits in Offspring. *Cell* **2016**, *165*, 1762–1775. https://doi.org/10.1016/j.cell.2016.06.001.
18. Poutahidis, T.; Kleinewietfeld, M.; Smillie, C.; Levkovich, T.; Perrotta, A.; Bhela, S.; Varian, B.J.; Ibrahim, Y.M.; Lakritz, J.R.; Kearney, S.M.; et al. Microbial Reprogramming Inhibits Western Diet-Associated Obesity. *PLoS ONE* **2013**, *8*, e68596. https://doi.org/10.1371/journal.pone.0068596.
19. Medicine, N.L. L. Reuteri DSM 17938 and L. Reuteri ATCC PTA 6475 in Moderate to Severe Irritable Bowel in Adults (Reuteri-IBS). 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT04037826 (accessed on 28 Feburary 2022).
20. Collins, N.; Han, S.-J.; Enamorado, M.; Link, V.M.; Huang, B.; Moseman, E.A.; Kishton, R.J.; Shannon, J.P.; Dixit, D.; Schwab, S.R.; et al. The Bone Marrow Protects and Optimizes Immunological Memory during Dietary Restriction. *Cell* **2019**, *178*, 1088–1101.e15. https://doi.org/10.1016/j.cell.2019.07.049.
21. West, C.L.; McVey Neufeld, K.-A.; Mao, Y.-K.; Stanisz, A.M.; Forsythe, P.; Bienenstock, J.; Barbut, D.; Zasloff, M.; Kunze, W.A. Identification of SSRI-Evoked Antidepressant Sensory Signals by Decoding Vagus Nerve Activity. *Sci. Rep.* **2021**, *11*, 21130. https://doi.org/10.1038/s41598-021-00615-w.
22. Campbell, S.; Macqueen, G. The Role of the Hippocampus in the Pathophysiology of Major Depression. *J. Psychiatry Neurosci.* **2004**, *29*, 417–426.
23. MacQueen, G.; Frodl, T. The Hippocampus in Major Depression: Evidence for the Convergence of the Bench and Bedside in Psychiatric Research? *Mol. Psychiatry* **2011**, *16*, 252–264. https://doi.org/10.1038/mp.2010.80.
24. Roddy, D.W.; Farrell, C.; Doolin, K.; Roman, E.; Tozzi, L.; Frodl, T.; O’Keane, V.; O’Hanlon, E. The Hippocampus in Depression: More Than the Sum of Its Parts? Advanced Hippocampal Substructure Segmentation in Depression. *Biol. Psychiatry* **2019**, *85*, 487–497. https://doi.org/10.1016/j.biopsych.2018.08.021.
25. Knapp, B.; Omasits, U.; Schreiner, W.; Epstein, M.M. A Comparative Approach Linking Molecular Dynamics of Altered Peptide Ligands and MHC with In Vivo Immune Responses. *PLoS ONE* **2010**, *5*, e11653. https://doi.org/10.1371/journal.pone.0011653.
26. Maric, M.; Arunachalam, B.; Phan, U.T.; Dong, C.; Garrett, W.S.; Cannon, K.S.; Alfonso, C.; Karlsson, L.; Flavell, R.A.; Cresswell, P. Defective Antigen Processing in GILT-Free Mice. *Science* **2001**, *294*, 1361–1365. https://doi.org/10.1126/science.1065500.
27. Singh, R.; Cresswell, P. Defective Cross-Presentation of Viral Antigens in GILT-Free Mice. *Science* **2010**, *328*, 1394–1398. https://doi.org/10.1126/science.1189176.
28. Fuentes-Pananá, E.M.; Bannish, G.; van der Voort, D.; King, L.B.; Monroe, J.G. Igα/Igβ Complexes Generate Signals for B Cell Development Independent of Selective Plasma Membrane Compartmentalization. *J. Immunol.* **2005**, *174*, 1245–1252. https://doi.org/10.4049/jimmunol.174.3.1245.
29. Siemasko, K.; Eisfelder, B.J.; Stebbins, C.; Kabak, S.; Sant, A.J.; Song, W.; Clark, M.R. Ig Alpha and Ig Beta Are Required for Efficient Trafficking to Late Endosomes and to Enhance Antigen Presentation. *J. Immunol.* **1999**, *162*, 6518–6525.
30. Liu, Y.; Steinhausen, K.; Bharwani, A.; Mian, M.F.; McVey Neufeld, K.-A.; Forsythe, P. Increased Persistence of Avoidance Behaviour and Social Deficits with L.Rhamnosus JB-1 or Selective Serotonin Reuptake Inhibitor Treatment Following Social Defeat. *Sci. Rep.* **2020**, *10*, 13485. https://doi.org/10.1038/s41598-020-69968-y.
31. Branco-de-Almeida, L.S.; Kajiya, M.; Cardoso, C.R.; Silva, M.J.B.; Ohta, K.; Rosalen, P.L.; Franco, G.C.N.; Han, X.; Taubman, M.A.; Kawai, T. Selective Serotonin Reuptake Inhibitors Attenuate the Antigen Presentation from Dendritic Cells to Effector T Lymphocytes. *FEMS Immunol. Med. Microbiol.* **2011**, *62*, 283–294. https://doi.org/10.1111/j.1574-695X.2011.00816.x.
32. Pinto, F.E.; Andrade, C. Interferon-Related Depression: A Primer on Mechanisms, Treatment, and Prevention of a Common Clinical Problem. *Curr. Neuropharmacol.* **2016**, *14*, 743–748. https://doi.org/10.2174/1570159X14666160106155129.
33. Inserra, A.; Mastronardi, C.A.; Rogers, G.; Licinio, J.; Wong, M.-L. Neuroimmunomodulation in Major Depressive Disorder: Focus on Caspase 1, Inducible Nitric Oxide Synthase, and Interferon-Gamma. *Mol. Neurobiol.* **2019**, *56*, 4288–4305. https://doi.org/10.1007/s12035-018-1359-3.
34. Maes, M.; Scharpé, S.; Meltzer, H.Y.; Okayli, G.; Bosmans, E.; D’Hondt, P.; Vanden Bossche, B.; Cosyns, P. Increased Neopterin and Interferon-Gamma Secretion and Lower Availability of L-Tryptophan in Major Depression: Further Evidence for an Immune Response. *Psychiatry Res.* **1994**, *54*, 143–160. https://doi.org/10.1016/0165-1781(94)90003-5.
35. Maes, M. Negative Immunoregulatory Effects of Antidepressants Inhibition of Interferon-γ and Stimulation of Interleukin-10 Secretion. *Neuropsychopharmacology* **1999**, *20*, 370–379. https://doi.org/10.1016/S0893-133X(98)00088-8.
36. Karimi, K.; Kandiah, N.; Chau, J.; Bienenstock, J.; Forsythe, P. A Lactobacillus Rhamnosus Strain Induces a Heme Oxygenase Dependent Increase in Foxp3+ Regulatory T Cells. *PLoS ONE* **2012**, *7*, e47556. https://doi.org/10.1371/journal.pone.0047556.
37. Forsythe, P.; Wang, B.; Khambati, I.; Kunze, W.A. Systemic Effects of Ingested Lactobacillus Rhamnosus: Inhibition of Mast Cell Membrane Potassium (IKCa) Current and Degranulation. *PLoS ONE* **2012**, *7*, e41234. https://doi.org/10.1371/journal.pone.0041234.
38. Maes, M.; Lambrechts, J.; Bosmans, E.; Jacobs, J.; Suy, E.; Vandervorst, C.; De Jonckheere, C.; Minner, B.; Raus, J. Evidence for a Systemic Immune Activation during Depression: Results of Leukocyte Enumeration by Flow Cytometry in Conjunction with Monoclonal Antibody Staining. *Psychol. Med.* **1992**, *22*, 45–53. https://doi.org/10.1017/S0033291700032712.
39. Kong, X.; Zhang, Z.; Fu, T.; Ji, J.; Yang, J.; Gu, Z. TNF-α Regulates Microglial Activation via the NF-ΚB Signaling Pathway in Systemic Lupus Erythematosus with Depression. *Int. J. Biol. Macromol.* **2019**, *125*, 892–900. https://doi.org/10.1016/j.ijbiomac.2018.12.146.
40. Wang, Y.; Xu, J.; Liu, Y.; Li, Z.; Li, X. TLR4-NF-κ B Signal Involved in Depressive-Like Behaviors and Cytokine Expression of Frontal Cortex and Hippocampus in Stressed C57BL/6 and Ob/Ob Mice. *Neural Plast.* **2018**, *2018*, 7254016. https://doi.org/10.1155/2018/7254016.
41. Yang, H.; Rudge, D.G.; Koos, J.D.; Vaidialingam, B.; Yang, H.J.; Pavletich, N.P. mTOR Kinase Structure, Mechanism and Regulation. *Nature* **2013**, *497*, 217–223. https://doi.org/10.1038/nature12122.
42. Hu, L.; Chen, F.; Wu, C.; Wang, J.; Chen, S.; Li, X.; Wang, J.; Wu, L.; Ding, J.; Wang, J.; et al. Rapamycin Recruits SIRT2 for FKBP12 Deacetylation during MTOR Activity Modulation in Innate Immunity. *iScience* **2021**, *24*, 103177. https://doi.org/10.1016/j.isci.2021.103177.
43. Chi, H. Regulation and Function of MTOR Signalling in T Cell Fate Decisions. *Nat. Rev. Immunol.* **2012**, *12*, 325–338. https://doi.org/10.1038/nri3198.8.
44. Weichhart, T.; Hengstschläger, M.; Linke, M. Regulation of Innate Immune Cell Function by mTOR. *Nat. Rev. Immunol.* **2015**, *15*, 599–614. https://doi.org/10.1038/nri3901.
45. Takeda, K.; Akira, S. STAT Family of Transcription Factors in Cytokine-Mediated Biological Responses. *Cytokine Growth Factor Rev.* **2000**, *11*, 199–207. https://doi.org/10.1016/S1359-6101(00)00005-8.
46. Jankovic, D.; Trinchieri, G. IL-10 or Not IL-10: That Is the Question. *Nat. Immunol.* **2007**, *8*, 1281–1283. https://doi.org/10.1038/ni1207-1281.
47. Shariq, A.S.; Brietzke, E.; Rosenblat, J.D.; Pan, Z.; Rong, C.; Ragguett, R.-M.; Park, C.; McIntyre, R.S. Therapeutic Potential of JAK/STAT Pathway Modulation in Mood Disorders. *Rev. Neurosci.* **2018**, *30*, 1–7. https://doi.org/10.1515/revneuro-2018-0027.
48. Al-Samhari, M.M.; Al-Rasheed, N.M.; Al-Rejaie, S.; Al-Rasheed, N.M.; Hasan, I.H.; Mahmoud, A.M.; Dzimiri, N. Possible Involvement of the JAK/STAT Signaling Pathway in N-Acetylcysteine-Mediated Antidepressant-like Effects. *Exp. Biol. Med.* **2016**, *241*, 509–518. https://doi.org/10.1177/1535370215619707.
49. Vincze, O.; Tökési, N.; Oláh, J.; Hlavanda, E.; Zotter, Á.; Horváth, I.; Lehotzky, A.; Tirián, L.; Medzihradszky, K.F.; Kovács, J.; et al. Tubulin Polymerization Promoting Proteins (TPPPs): Members of a New Family with Distinct Structures and Functions. *Biochemistry* **2006**, *45*, 13818–13826. https://doi.org/10.1021/bi061305e.
50. Leong, M.L.L.; Maiyar, A.C.; Kim, B.; O’Keeffe, B.A.; Firestone, G.L. Expression of the Serum- and Glucocorticoid-Inducible Protein Kinase, Sgk, Is a Cell Survival Response to Multiple Types of Environmental Stress Stimuli in Mammary Epithelial Cells. *J. Biol. Chem.* **2003**, *278*, 5871–5882. https://doi.org/10.1074/jbc.M211649200.
51. Yoo, D.; Kim, B.Y.; Campo, C.; Nance, L.; King, A.; Maouyo, D.; Welling, P.A. Cell Surface Expression of the ROMK (Kir 1.1) Channel Is Regulated by the Aldosterone-Induced Kinase, SGK-1, and Protein Kinase A. *J. Biol. Chem.* **2003**, *278*, 23066–23075. https://doi.org/10.1074/jbc.M212301200.
52. Eylenstein, A.; Gehring, E.; Heise, N.; Shumilina, E.; Schmidt, S.; Szteyn, K.; Münzer, P.; Nurbaeva, M.K.; Eichenmüller, M.; Tyan, L.; et al. Stimulation of Ca2+-channel Orai1/STIM1 by Serum‐and Glucocorticoid‐inducible Kinase 1 (SGK1). *FASEB J.* **2011**, *25*, 2012–2021. https://doi.org/10.1096/fj.10-178210.
53. Mo, J.-S.; Ann, E.-J.; Yoon, J.-H.; Jung, J.; Choi, Y.-H.; Kim, H.-Y.; Ahn, J.-S.; Kim, S.-M.; Kim, M.-Y.; Hong, J.-A.; et al. Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) Controls Notch1 Signaling by Downregulation of Protein Stability through Fbw7 Ubiquitin Ligase. *J. Cell Sci.* **2011**, *124*, 100–112. https://doi.org/10.1242/jcs.073924.
54. Dattilo, V.; Amato, R.; Perrotti, N.; Gennarelli, M. The Emerging Role of SGK1 (Serum- and Glucocorticoid-Regulated Kinase 1) in Major Depressive Disorder: Hypothesis and Mechanisms. *Front. Genet.* **2020**, *11*, 826. https://doi.org/10.3389/fgene.2020.00826.
55. Anacker, C.; Cattaneo, A.; Musaelyan, K.; Zunszain, P.A.; Horowitz, M.; Molteni, R.; Luoni, A.; Calabrese, F.; Tansey, K.; Gennarelli, M.; et al. Role for the Kinase SGK1 in Stress, Depression, and Glucocorticoid Effects on Hippocampal Neurogenesis. *Proc. Natl. Acad. Sci.* *USA* **2013**, *110*, 8708–8713. https://doi.org/10.1073/pnas.1300886110.
56. Licznerski, P.; Duric, V.; Banasr, M.; Alavian, K.N.; Ota, K.T.; Kang, H.J.; Jonas, E.A.; Ursano, R.; Krystal, J.H.; Duman, R.S. Decreased SGK1 Expression and Function Contributes to Behavioral Deficits Induced by Traumatic Stress. *PLoS Biol.* **2015**, *13*, e1002282. https://doi.org/10.1371/journal.pbio.1002282.
57. Zhang, K.; Pan, X.; Wang, F.; Ma, J.; Su, G.; Dong, Y.; Yang, J.; Wu, C. Baicalin Promotes Hippocampal Neurogenesis via SGK1- and FKBP5-Mediated Glucocorticoid Receptor Phosphorylation in a Neuroendocrine Mouse Model of Anxiety/Depression. *Sci. Rep.* **2016**, *6*, 30951. https://doi.org/10.1038/srep30951.
58. Drabek, K.; van de Peppel, J.; Eijken, M.; van Leeuwen, J.P. GPM6B Regulates Osteoblast Function and Induction of Mineralization by Controlling Cytoskeleton and Matrix Vesicle Release. *J. Bone Miner. Res.* **2011**, *26*, 2045–2051. https://doi.org/10.1002/jbmr.435.
59. Fjorback, A.W.; Müller, H.K.; Wiborg, O. Membrane Glycoprotein M6B Interacts with the Human Serotonin Transporter. *J. Mol. Neurosci.* **2009**, *37*, 191–200. https://doi.org/10.1007/s12031-008-9092-4.
60. Haase, J.; Grudzinska-Goebel, J.; Müller, H.K.; Münster-Wandowski, A.; Chow, E.; Wynne, K.; Farsi, Z.; Zander, J.-F.; Ahnert-Hilger, G. Serotonin Transporter Associated Protein Complexes Are Enriched in Synaptic Vesicle Proteins and Proteins Involved in Energy Metabolism and Ion Homeostasis. *ACS Chem. Neurosci.* **2017**, *8*, 1101–1116. https://doi.org/10.1021/acschemneuro.6b00437.
61. Fuchsova, B.; Alvarez Juliá, A.; Rizavi, H.S.; Frasch, A.C.; Pandey, G.N. Altered Expression of Neuroplasticity-Related Genes in the Brain of Depressed Suicides. *Neuroscience* **2015**, *299*, 1–17. https://doi.org/10.1016/j.neuroscience.2015.04.057.
62. Mariani, N.; Cattane, N.; Pariante, C.; Cattaneo, A. Gene Expression Studies in Depression Development and Treatment: An Overview of the Underlying Molecular Mechanisms and Biological Processes to Identify Biomarkers. *Transl. Psychiatry* **2021**, *11*, 354. https://doi.org/10.1038/s41398-021-01469-6.
63. Rodriguiz, R.M.; Wilkins, J.J.; Creson, T.K.; Biswas, R.; Berezniuk, I.; Fricker, A.D.; Fricker, L.D.; Wetsel, W.C. Emergence of Anxiety-like Behaviours in Depressive-like Cpefat/Fat Mice. *Int. J. Neuropsychopharmacol.* **2013**, *16*, 1623–1634. https://doi.org/10.1017/S1461145713000059.
64. Cheng, Y.; Cawley, N.X.; Yanik, T.; Murthy, S.R.K.; Liu, C.; Kasikci, F.; Abebe, D.; Loh, Y.P. A Human Carboxypeptidase E/NF-Α1 Gene Mutation in an Alzheimer’s Disease Patient Leads to Dementia and Depression in Mice. *Transl. Psychiatry* **2016**, *6*, e973–e973. https://doi.org/10.1038/tp.2016.237.
65. Araki, Y.; Kawano, T.; Taru, H.; Saito, Y.; Wada, S.; Miyamoto, K.; Kobayashi, H.; Ishikawa, H.O.; Ohsugi, Y.; Yamamoto, T.; et al. The Novel Cargo Alcadein Induces Vesicle Association of Kinesin-1 Motor Components and Activates Axonal Transport. *EMBO J.* **2007**, *26*, 1475–1486. https://doi.org/10.1038/sj.emboj.7601609.
66. Davies, M.N.; Krause, L.; Bell, J.T.; Gao, F.; Ward, K.J.; Wu, H.; Lu, H.; Liu, Y.; Tsai, P.-C.; Collier, D.A.; et al. Hypermethylation in the ZBTB20 Gene Is Associated with Major Depressive Disorder. *Genome Biol.* **2014**, *15*, R56. https://doi.org/10.1186/gb-2014-15-4-r56.
67. Li, S.; Cao, W.; Zhou, S.; Ma, M.; Zhang, W.; Li, F.; Li, C. Expression of Cntn1 Is Regulated by Stress and Associated with Anxiety and Depression Phenotypes. *Brain. Behav. Immun.* **2021**, *95*, 142–153. https://doi.org/10.1016/j.bbi.2021.03.012.
68. Dobin, A.; Davis, C.A.; Schlesinger, F.; Drenkow, J.; Zaleski, C.; Jha, S.; Batut, P.; Chaisson, M.; Gingeras, T.R. STAR: Ultrafast Universal RNA-Seq Aligner. *Bioinformatics* **2013**, *29*, 15–21. https://doi.org/10.1093/bioinformatics/bts635.
69. Patro, R.; Duggal, G.; Love, M.I.; Irizarry, R.A.; Kingsford, C. Salmon Provides Fast and Bias-Aware Quantification of Transcript Expression. *Nat. Methods* **2017**, *14*, 417–419. https://doi.org/10.1038/nmeth.4197.
70. Saunders, C.T.; Wong, W.S.W.; Swamy, S.; Becq, J.; Murray, L.J.; Cheetham, R.K. Strelka: Accurate Somatic Small-Variant Calling from Sequenced Tumor–Normal Sample Pairs. *Bioinformatics* **2012**, *28*, 1811–1817. https://doi.org/10.1093/bioinformatics/bts271.
71. Love, M.I.; Huber, W.; Anders, S. Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data with DESeq2. *Genome Biol.* **2014**, *15*, 550.
72. Benjamini, Y.; Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J. R. Stat. Soc. Ser. B* **1995**, *57*, 289–300. https://doi.org/10.1111/j.2517-6161.1995.tb02031.x.
73. Wickham, H. *Ggplot2: Elegant Graphics for Data Analysis*; Springer: New York, NY, USA, 2016; ISBN 978-3-319-24277-4.
74. Luo, W.; Friedman, M.S.; Shedden, K.; Hankenson, K.D.; Woolf, P.J. GAGE: Generally Applicable Gene Set Enrichment for Pathway Analysis. *BMC Bioinform.* **2009**, *10*, 161. https://doi.org/10.1186/1471-2105-10-161.
75. Luo, W.; Brouwer, C. Pathview: An R/Bioconductor Package for Pathway-Based Data Integration and Visualization. *Bioinformatics* **2013**, *29*, 1830–1831. https://doi.org/10.1093/bioinformatics/btt285.
76. Litteljohn, D.; Nelson, E.; Hayley, S. IFN-Υ Differentially Modulates Memory-Related Processes under Basal and Chronic Stressor Conditions. *Front. Cell. Neurosci.* **2014**, *8*, 391. https://doi.org/10.3389/fncel.2014.00391.
77. Lambert, G.; Johansson, M.; Ågren, H.; Friberg, P. Reduced Brain Norepinephrine and Dopamine Release in Treatment-Refractory Depressive Illness. *Arch. Gen. Psychiatry* **2000**, *57*, 787. https://doi.org/10.1001/archpsyc.57.8.787.
78. Gulbins, A.; Grassmé, H.; Hoehn, R.; Kohnen, M.; Edwards, M.J.; Kornhuber, J.; Gulbins, E. Role of Janus-Kinases in Major Depressive Disorder. *Neurosignals* **2016**, 71–80. https://doi.org/10.1159/000442613.
79. Kubera, M.; Basta-Kaim, A.; Papp, M. The Effect of Chronic Treatment with Imipramine on the Immunoreactivity of Animals Subjected to a Chronic Mild Stress Model of Depression. *Immunopharmacology* **1995**, *30*, 225–230. https://doi.org/10.1016/0162-3109(95)00026-P.
80. Fatima, A.; Hoeber, J.; Schuster, J.; Koshimizu, E.; Maya-Gonzalez, C.; Keren, B.; Mignot, C.; Akram, T.; Ali, Z.; Miyatake, S.; et al. Monoallelic and Bi-Allelic Variants in NCDN Cause Neurodevelopmental Delay, Intellectual Disability, and Epilepsy. *Am. J. Hum. Genet.* **2021**, *108*, 739–748. https://doi.org/10.1016/j.ajhg.2021.02.015.
81. Pan, Y.; Zhang, W.-Y.; Xia, X.; Kong, L.-D. Effects of Icariin on Hypothalamic-Pituitary-Adrenal Axis Action and Cytokine Levels in Stressed Sprague-Dawley Rats. *Biol. Pharm. Bull.* **2006**, *29*, 2399–2403. https://doi.org/10.1248/bpb.29.2399.
82. Wei, K.; Xu, Y.; Zhao, Z.; Wu, X.; Du, Y.; Sun, J.; Yi, T.; Dong, J.; Liu, B. Icariin Alters the Expression of Glucocorticoid Receptor, FKBP5 and SGK1 in Rat Brains Following Exposure to Chronic Mild Stress. *Int. J. Mol. Med.* **2016**, *38*, 337–344. https://doi.org/10.3892/ijmm.2016.2591.
83. Wesseling, H.; Rahmoune, H.; Tricklebank, M.; Guest, P.C.; Bahn, S. A Targeted Multiplexed Proteomic Investigation Identifies Ketamine-Induced Changes in Immune Markers in Rat Serum and Expression Changes in Protein Kinases/Phosphatases in Rat Brain. *J. Proteome Res.* **2015**, *14*, 411–421. https://doi.org/10.1021/pr5009493.